Lixisenatide vs Semaglutide

Lixisenatide (brand names Adlyxin or Soliqua) is a GLP-1 drug approved only for type 2 diabetes, while semaglutide (brand names Ozempic, Wegovy, or Rybelsus) is also approved for obesity, chronic kidney disease, and reducing cardiovascular risk. Both are GLP-1 receptor agonists, but semaglutide is taken as a weekly injection (Ozempic, Wegovy) or a daily pill (Rybelsus), whereas lixisenatide is taken as a daily injection (Adlyxin) or combined with insulin in Soliqua.

AI summary of the sources below.